Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Repurposed Therapeutics Inc. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is handled by 1 distinct examiner and is situated within 1 distinct art unit. The presence of only one active matter suggests a focused engagement with the patent office in this specific technology sector, as the entire pending portfolio is concentrated in a single examination channel. This structure streamlines the management of the company's current intellectual property assets by limiting the number of involved USPTO personnel.
The busiest examiner for the company is VAJDA, KRISTIN ANN, who is assigned 1 pending office action. Given the total volume of pending work, VAJDA, KRISTIN ANN manages the entirety of the current workload for Repurposed Therapeutics Inc. within the Biotechnology & Pharmaceuticals area. This singular focus allows for a concentrated prosecution strategy, as the applicant only needs to address the specific requirements and feedback of this one examiner. Practitioners can dedicate their resources to understanding the unique preferences and historical actions of this individual.
Because the portfolio involves 1 distinct art unit, the technical scope of the pending work is likely confined to a specific sub-field. Practitioners can focus their efforts on the examination trends and guidelines specific to this unit without the need to reconcile conflicting approaches from different USPTO divisions. The lack of multiple pending actions or examiners simplifies the administrative burden and allows for a targeted approach to securing patent protection. This concentration of effort is a defining characteristic of the company's current prosecution profile.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAJDA, KRISTIN ANN | 1 | 83.8% | +11.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18230236 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MOTION SICKNESS AND EMESIS | VAJDA, KRISTIN ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18230236 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MOTION SICKNESS AND EMESIS | VAJDA, KRISTIN ANN | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18230236 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MOTION SICKNESS AND EMESIS | VAJDA, KRISTIN ANN | 1622 | §103 | Non-Final OA | — | Pending | Aug 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRepurposed Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kristin Ann Vajda has the most, with 1 of Repurposed Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
